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Abstract
Background: The use of neurotrophic factors to treat Alzheimer’s disease (AD) is hindered by their blood–brain
barrier impermeability, short half-life, and severe side effects. Peptide 021 (P021) is a neurotrophic/neurogenic tetrapeptide that was derived from the most active region of the ciliary neurotrophic factor (CNTF) by epitope mapping.
Admantylated glycine was added to its C-terminal to increase its blood–brain barrier permeability and decrease its
degradation by exopeptidases to make it druggable. Here, we report on the preventive effect of P021 in 3 × Tg-AD,
a transgenic mouse model of AD.
Methods: P021 was administered in the diet at 3 months, i.e., 6–9 months before any overt amyloid beta (Aβ) or
tau pathology, and during the period of synaptic compensation, and was continued until 21 months in 3 × Tg-AD
mice. The 3 × Tg-AD mice and wild-type (WT) mice were treated identically but with a vehicle-only diet serving as
controls. The effects of P021 on neurogenesis, dendritic and synaptic markers, and cognitive performance were
investigated.
Results: We found that P021 treatment was able to rescue dendritic and synaptic deficits, boost neurogenesis, and
reverse cognitive impairment in 3 × Tg-AD mice.
Conclusions: Availability of appropriate neurotrophic support during the period of synaptic compensation can
prevent synaptic deficit and cognitive impairment, and P021 is a promising neurotrophic compound for this purpose.
Keywords: Alzheimer’s disease, 3 × Tg-AD mice, Synaptic plasticity, Cognitive deficit, Synaptic compensation,
Neurotrophic compound, Neurogenesis, Prevention

Background
Alzheimer’s disease (AD) is characterized histopathologically by an extensive neurodegeneration, especially of
the hippocampus, that is associated with intraneuronal
neurofibrillary tangles of abnormally hyperphosphorylated tau and extracellular deposition of amyloid beta
(Aβ) as plaques. Neurodegeneration that results in
dementia is seen both as neuronal and synaptic loss.
During the last two decades, the vast majority of the
therapeutic approaches have focused mainly on inhibiting neurodegeneration by prevention or clearance of Aβ
plaques. However, so far results have been disappointing
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and, to date, no disease-modifying drug has been approved for the treatment of AD. These repeated failures
could be due to either inhibition of Aβ alone not being
sufficient, and/or that the treatment was initiated too
late to be effective.
During the disease process, the AD brain tries to compensate for synaptic and neuronal loss by initiating the
dentate gyrus (DG) neurogenesis and dendritic sprouting
but, because of insufficient appropriate neurotrophic
support, this attempt does not succeed in replacing
neuronal loss with new mature functional neurons nor
in replacing the lost dendrites and synapses [1–7].
A key mechanism of neuronal loss and neurogenesis
and synaptic plasticity deficits could be the imbalance of
neurotrophic factors [7]. Indeed, it is known that the
levels of fibroblast growth factor (FGF)2 are increased
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and that of brain-derived neurotrophic factor (BDNF)
and neurotrophin-4 are decreased in the AD brain
[8–10]. Thus, one therapeutic approach is to provide
the diseased brain with neurotrophic support especially during the period of synaptic compensation to
help the self-repair attempt of the brain.
Previously, we showed that ciliary neurotrophic factor
(CNTF) can counteract the mitogenic effect of FGF2
[11] and, based on this finding, we developed a CNTF
peptidergic compound, P021, which can increase the
transcription of BDNF, enhance neurogenesis and neuronal plasticity, and improve cognitive performance in
mice and rats [12, 13]. Here, we investigated the beneficial therapeutic effect of boosting the neurotrophic environment by initiating treatment with P021 in the diet
at 3 months of age (i.e., around 6–9 months before any
overt Aβ or tau pathology, and during the period of synaptic compensation) and continuing for approximately
18 months in a triple transgenic mouse model of AD
(3 × Tg-AD mice). This mouse model that overexpresses
a human βAPPSwe and tau P301L in PS1M146v knock-in
background, although a genetic mixture of AD and
fronto-temporal dementia mutations, shows synaptic
compensation associated with cognitive impairment at the
age of 12–16 weeks, and Aβ plaque and tau pathologies
several months later [14, 15]. The initiation of treatment
with P021 during the period of synaptic compensation
rescued neurogenesis and synaptic deficits and reversed
cognitive impairment at around 9 and 15–16 months
posttreatment in 3 × Tg-AD mice.

Methods
Animals and housing

Animals were housed and bred following our Institutional Animal Care and Use Committee (IACUC) guidelines, according to the PHS Policy on Human Care and
Use of Laboratory Animals (revised January 2013).
Animals were group-housed at five animals per cage
with a standard temperature of 22 ± 1°C and a lightcontrolled environment (12:12 h light/dark cycle), and
with ad libitum access to food and water. Breeding pairs
of the 3 × Tg-AD mice expressing three human mutation
transgenes (APPSwe mutation, tau P301L mutation, and
Presenilin1 (PS1) knock-in) and wild-type (WT) agematched control mice from the same genetic background (hybrid 129/Sv × C57BL/6) were obtained from
Dr. Frank LaFerla through the Jackson laboratory (New
Harbor, ME, USA). In this mouse model the extracellular
deposition of the Aβ plaques starts at around 9 months in
the neocortex and expands to the hippocampus at around
12 months, and the formation of neurofibrillary tangles
(NFT) starts at around 12 months in the limbic areas and
expands to the other brain regions several months later.
Furthermore, Aβ and tau pathologies develop in a
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progressive age-dependent manner with similar brain distribution of the lesions, as in AD. However, 3 × Tg-AD
mice are homozygous and were independently bred from
129/Sv × C57BL/6 WT mice, and thus the latter were not
ideal littermate controls to the transgenic mice. A period
of acclimatization from 45 min to 1 h was accorded to the
animals before each behavioral test to habituate to the
new environment. Only female 3 × Tg-AD and agematched WT control mice were used in the study because,
similar to humans, female 3 × Tg-AD mice show more aggressive pathology with earlier cognitive impairment,
more Aβ deposition, and a higher and earlier deficit in
neurogenesis than their male counterparts [16–18]; the female transgenic mice show overt Aβ and tau pathologies
at around 9 and 12 months, respectively [14]. While
originally both male and female 3 × Tg-AD mice were reported by Dr. La Ferla to show AD pathology, the subsequent studies found that only female 3 × Tg-AD animals
show more consistent and aggressive pathology [16–19].
Indeed, they are known to exhibit more aggressive Aβ
pathology compared to males during the plaque-bearing
stage, and Aβ pathology becomes more evident at 14
months in females compared to males. Furthermore, at 16
months of age female mice exhibit higher levels of soluble
Aβ1–40 and 1–42 as well as total Aβ levels, and the difference becomes clearer at 23 months. Female mice have
higher Aβ secretase activity and less efficient Aβ degradation than males, and there is no difference in tau pathology [17, 18]. To have consistent and reliable data that
can be replicated we thus decided to use female mice instead of using both sexes. Animals other than the ones
employed for behavioral studies were employed for immunohistochemical and biochemical studies to exclude any
effect of behavioral studies on neurogenesis and synaptic
plasticity (Additional file 1: Table S1).
Study design

Three-month-old female WT animals (n = 41), 3 × Tg-AD
mice treated with a vehicle diet (3 × Tg-AD-vh; n = 35),
and 3 × Tg-AD mice treated with a P021 diet (3 × Tg-ADP021; n = 32) were used in the study. The animals were divided into two sets: one set of WT (n = 20), 3 × Tg-AD-vh
(n = 15), and 3 × Tg-AD-P021 (n = 14) animals were used
for behavioral studies, and another set of mice that did
not go through behavioral studies (WT (n = 21), 3 × TgAD-vh (n = 20), and 3 × Tg-AD-P021 (n = 18)) were
employed for immunohistochemical and biochemical analyses. The mice that were employed for behavioral analyses were used to study the effect of P021 on cognition.
At 9 months after treatment with P021 the Morris Water
Maze task was conducted. Then, at 15–16 months after
treatment, the mice were tested by the object location
task. Brain samples from mice that were not tested behaviorally were taken at the age of 3 months just before the
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start of the treatment as a baseline measure and then at 9,
15, and 18 months after treatment with P021 (Fig. 1b).
P021 was given in the food diet at a concentration of 60
nmol/g feed.
P021 treatment

At approximately 3 months of age, the animals were divided into three groups: one group of 3 × Tg-AD-P021
(n = 32) treated with 60 nmol P021/g feed in the diet; a
second group of 3 × Tg-AD-vh (n = 35) treated with the
same diet but without P021; and a third group of WT
(n = 41) treated with the same diet but without P021.
P021 was formulated by Research Diets (New Brunswick, NJ, USA). Food consumption was recorded every
2 weeks and body weight every month. The average
mouse food consumption was ~2.7 g feed/day.
Design and synthesis of P021

The chemical structure of P021 is shown in Fig. 1a. It is a
pentapeptide (Ac-DGGLAG-NH2; molecular weight 578.3)
generated by the addition of adamantylated glycine at the
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C-terminus of CNTF tetrapeptide (amino acid residues
148–151). The adamantylated glycine was added to P021
to increase its blood–brain barrier permeability and decrease its degradation by carboxy peptidases [8, 13, 20].
P021 was synthesized and purified by reverse phase HPLC
to >96% purity as described previously [13]. The sequence
of P021 was confirmed by mass spectrometry.
P021 stability in plasma, gastric and intestinal juices, and
blood–brain barrier permeability

P021 has >95% stability in artificial gastric juice over
30 min, ~100% stability in intestinal fluid over 120
min, a plasma stability >3 h, and is blood–brain barrier permeable [21].
Behavioral studies

At 9 months posttreatment mice were tested for spatial
reference memory by the Morris Water Maze task [22]
and at 15–16 months posttreatment by a novel object
location task.
Morris Water Maze task

Fig. 1 Chemical structure of P021 and study design. Female 3 × TgAD 3-month-old mice were put on mouse chow (AIN-76, Research
Diets, New Brunswick, NJ, USA) that contained 60 nmol P021/g feed.
As controls, both 3 × Tg-AD mice and gender-, age-, and genetic
background-matched WT mice (129/Sv × C57BL/6) were treated with
the vehicle diet. On average the mice consumed ~2.7 g diet/day
which amounted to 60 nmol × 2.7 = 162 nmol P021 per mouse per
day. At 9, 15, and 18 months posttreatment, mice were sacrificed
and their brains studied for expressions and levels of various proteins
associated with cognition both immunohistochemically and
biochemically (see Figs. 2, 3, 4, 5, 6 and 7). Separate sets of animals
were treated as above with a P021 or vehicle diet and tested
behaviorally at 9 and 15–16 month posttreatment (Figs. 8 and 9).
a The chemical structure of P021. b Study design. 3 × Tg-AD-P021
3 × Tg-AD mice treated with a P021 diet, 3 × Tg-AD-vh 3 × Tg-AD
mice treated with a vehicle diet, IHC immunohistochemical staining,
WT wild-type control mice

The Morris Water Maze task was performed according
to a procedure adapted from that described by Morris et
al. [22]. Briefly, animals were divided into three groups:
3 × Tg-AD-vh (n = 15), 3 × Tg-AD-P021 (n = 14), and
age-matched WT control mice (n = 20). A circular pool
tank 180 cm in diameter was used and a 13-cm escape
platform was submerged 1 cm below the surface of
water in the Northwest quadrant. The escape platform
was invisible to mice since the water was made opaque
by a white nontoxic chalk. During each trial each animal
was trained starting from a different quadrant so that it
learns to associate the spatial cues to the place of the
submerged platform. The water was kept at a constant
temperature of 21 ± 1°C. Animals were trained for 4 consecutive days, with four trials per day. During each trial
each animal was given 90 s to find the escape platform
otherwise it was gently guided to it. The first probe trial
(PT1) was given 24 h after the last training session and
the second probe trial (PT2) was given 20 days after the
first probe trial. Each animal was given 60 s to look for the
previous place of the platform. Recording of the behavior
of each mouse was performed using a Samsung digital
camera (SDC 4304) mounted on the ceiling; SMART version 2.0.14 software (Pan Lab/San Diego Instruments) was
used for tracking and timing of each trial.
Object location task

The object location task in the open field is a test for
short-term spatial memory, which is mainly hippocampaldependent. In this test, the 18-month-old animals were
required to identify the location of the object as novel or
familiar based on a previous experience. The test consists
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of a habituation phase, a sample phase, and a test phase.
During the habituation phase animals underwent a total
of six sessions, two sessions/day, and each session lasted
10 min within 2 h of intertrial interval. Neophobia measurements, in which an object was put in the center of the
arena and the amount of exploration time was recorded,
were performed during the first habituation phase.
Twenty-four hours after the last habituation session the
sample phase and the test phase of the novel object location were conducted. During the sample phase two identical objects were placed symmetrically in two different
places, each 15 cm away from the corner, and animals
were allowed to explore them for 5 min. One hour later,
in the test phase, one of the two objects was moved to a
new location 15 cm away from the corner, in a symmetrical position to the familiar one, and the time spent exploring each object was recorded. To evaluate cognitive
performance a discrimination index was calculated as follows: ((time exploring the new location – time exploring
familiar location)/total time exploring both locations) ×
100. Mice were considered to be impaired if they spent
more time investigating the familiar location than the
novel one. After each trial the objects were removed and
cleaned with 70% alcohol to remove any olfactory cues.
Tissue processing

For immunohistochemical and biochemical analysis the
animals were anesthetized using an overdose of avertin
and then transcardially perfused using 0.1 M phosphatebuffered saline (PBS). The left hemisphere was dissected
into the hippocampus and cortex (forebrain) and was
employed for biochemical analysis. The right hemisphere
was immersion-fixed with 4% paraformaldehyde in 0.1
M PBS for 24–48 h at 4°C then cryoprotected with 30%
sucrose in 0.1 M PBS for 48–72 h at 4°C. Sagittal sections of 40 μm thickness were cut using a freezingsliding microtome and were stored in glycol antifreeze
solution at –20°C until used for immunohistochemical
analysis.
Immunohistochemistry

For immunohistochemistry four to five animals per
group were chosen randomly. Every fifth section, five to
six sections per mouse, were used for intensity-scanning
analysis. For immunofluorescence, free-floating sections
recovered from the glycol antifreeze solution were
washed three times in 1× PBS for 15 min and then incubated in 0.5% Triton-X100 in PBS for 15 min. Sections
were then washed three times in 1× PBS for 15 min each
and blocked in 5% normal goat serum containing 0.05%
Tween-20 and 0.05% Triton X-100 for 45 min. Sections
were then incubated overnight at 4°C with the corresponding primary antibodies (see Additional file 1: Table
S2 for all the antibodies that were used in this study).
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Treatment with the primary antibody was followed by
treatment with the corresponding secondary fluorescent
antibody, either Alexa 488-conjugated goat antimouse
IgG antibody (1:500; Molecular Probes, Carlsbad, CA,
USA) or CY3-conjugated goat antirabbit antibody
(1:500; Jackson Laboratory, Bar Harbor, Maine, USA) for
2 h at room temperature protected from light. Sections
were washed three times with 1× PBS for 20 min each
and then mounted on microscope slides with fluorogel
mounting medium (Electron microscopy, Hatfield, PA,
USA). All the slides were then covered with coverslips
and stored at 4°C until analyzed by confocal microscopy
under identical conditions. For all the staining, maximum projection images were generated using the average of 15 Z-stacks using the 20× objective of a Nikon
90i fluorescent microscope equipped with a Nikon C1
three-laser confocal system and a Nikon DS U1 digital
camera. The entire area of the DG, CA1 (stratum radiatum and stratum pyramidae), CA3 (stratum oriens,
stratum radiatum, and stratum pyramidae), and parietal
association cortex (all six layers) were analyzed. For each
section the micrographs were transformed to grayscale
using the imageJ software and then each picture was
thresholded so that all the staining in the section with
the background was quantified. Mean pixel intensity was
measured for each brain region using the Image J software package (NIH). The area to be analyzed was selected and converted to greyscale then the threshold was
adjusted and the mean pixel intensity of the region of
interest was quantified.
To study neurogenesis, doublecortin (DCX) and Ki67
double immunohistochemical staining was performed.
The same procedure as stated above was used for the
immunohistochemical staining with the addition of the
extra step of antigen retrieval. Sections were then counterstained with the nuclear staining TO-PRO-3 iodide
(1:1000; Invitrogen, Camarillo, CA, USA) for 30 min and
then washed two times for 20 min. Five mice per group
and five sections (every tenth section) per brain per
mouse were analyzed. All sections were carefully investigated for DCX-positive and the Ki67-positive staining.
Labeled cells in the granule cell layer and the hilus of
the DG of the hippocampus were manually quantified
using a 40× oil objective of a Nikon 90i fluorescent
microscope. The number of DCX-positive staining cells
and Ki-67-positive cells was reported as the percent of
control.
Western blots

The brain tissue stored at –80°C was processed as described previously [21, 23]. The protein concentration of
each brain homogenate was determined by the Pierce 660
nm protein assay kit (Pierce Biotechnology, Rockford, IL
USA). The tissue homogenates were boiled in Laemmli’s

Baazaoui and Iqbal Alzheimer's Research & Therapy (2017) 9:45

buffer for 5 min and then subjected to 7.5% or 10% SDSpolyacrylamide gel electrophoresis followed by transfer of
separated proteins on 0.45-μm Immobilon-P membrane
(Millipore, Bedford, MA, USA). The blots were developed
using the corresponding primary antibodies (Additional
file 1: Table S2). Rabbit monoclonal antiGAPDH (1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
used for the development of the blots as a loading control.
The corresponding horseradish peroxidase-conjugated
affinity-pure goat antimouse IgG ((Heavy (H) + Light (L))
and antirabbit IgG (H + L) secondary antibodies were used
(1:5000; Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA, USA). The blots were visualized using
enhanced chemiluminescence (ECL) reagents (Pierce,
Rockford, IL, USA). The ECL films of the blots were
scanned and then analyzed using Image J (NIH) and Multigauge software (Fuji Photo Film, Co. Ltd). The final
quantification of the protein’s band intensity is the result
of the subtraction of the background from the original intensity divided by the GAPDH original intensity minus
the background. Statistical analysis was conducted using
the GraphPad Prism software package, version 5.0 (GraphPad Software Inc., La Jolla, CA, USA), or the Stata 13 statistical package (StataCorp, College Station, TX, USA).
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differentiated neurons. We studied the expression of
MAP2 immunohistochemically and found a trend toward
a decrease in the CA1 (Fig. 2a and e; two-tailed Student’s t
test, p = 0.05) and a significant decrease in the DG (Fig. 2a
and e; two-tailed Student’s t test, p = 0.0429). Similarly,
Western blot analysis of the hippocampus showed a significant decrease in MAP2 level (Fig. 3b and c; two-tailed
Student’s t test, p = 0.01). Synaptophysin expression was

Statistical analysis

The Stata and GraphPad Prism 5 (GraphPad Software
Inc, La Jolla, CA, USA) were used for statistical analysis.
Tests of scalar predictors were performed with regression models in Stata 13 (StataCorp, College Station, TX,
USA). For multiple group comparisons one-way analysis
of variance (ANOVA) followed by Tukey’s post-hoc tests
and two-way ANOVA followed by the Bonferroniadjusted test were used. For all other comparisons
(including intergroup comparisons) Student’s t test was
used. Data are presented as mean ± SD. For all analyses
p < 0.05 was considered significant.

Results
Preventive effect of P021 on synaptic plasticity
Synaptic deficit in 3 × Tg-AD mice at 3 months of age
before the start of the treatment

In a previous study we showed that 3 × Tg-AD mice
undergo synaptic compensation and are cognitively impaired at around 3 months [15]. Our aim was to start
the treatment with P021 very early in the disease process
at around the period of synaptic compensation. We analyzed brain tissues of 3-month-old 3 × Tg-AD mice before the start of the treatment. Along with the synaptic
markers we also investigated the expression level of the
dendritic marker microtubule-associated protein 2
(MAP2). MAP2 is localized in the somato-dendritic
compartment, including the spine, and thus serves as a
very useful putative synaptic marker and a marker of

Fig. 2 Dendritic and synaptic deficits in 3 × Tg-AD mice at 3 months of
age. Expressions of dendritic and synaptic markers were studied
immunohistochemically in 3-month-old female 3 × Tg-AD fed a vehicle
diet (Tg-AD vh) and control wild-type (WT) mice. a Immunohistochemical
staining of MAP2 in the CA1 (stratum radiatum and stratum pyramidae)
and dentate gyrus (DG; entire area); b synaptophysin in CA3 (stratum
oriens, stratum radiatum, and stratum pyramidae) and DG; c PSD95 in the parietal cortex (all six layers); d NR1 in the parietal cortex;
e quantification of immunohistochemical staining by mean pixel
intensity. At the age of 3 months the 3 × Tg-AD mice show a
decrease in the level of expression of several synaptic proteins
compared to WT. *p < 0.05, **p < 0.01, by t test. Scale bars = 100
μm. WT, n = 5; 3 × Tg-AD, n = 5. Each maximum projection picture
to be analyzed was converted to grayscale and each area to be
analyzed was selected, the threshold was adjusted, and the mean
pixel intensity of the region of interest was quantified. Quantification is
shown as mean ± SD
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Fig. 3 Decreases in levels of cognition-associated proteins in 3-month-old 3 × Tg-AD mice fed a vehicle diet (Tg-AD vh). Western blots of a the
cortex and b the hippocampus. c Relative quantification of the blots shown in a and b. All blots were normalized against the loading control
GAPDH. The 3 × Tg-AD mice show a decrease in levels of several proteins compared to the control wild-type (WT). *p <0.05, **p < 0.01, by t test.
WT, n = 6; 3 × Tg-AD vh, n = 6. Quantification is shown as mean ± SD

decreased both in the CA3 (Fig. 2b and e; two-tailed
Student’s t test, p = 0.0209) and the DG (Fig. 2b and e;
two-tailed Student’s t test, p = 0.0044). The PSD-95 expression showed a significant difference between the WT
and 3 × Tg-AD mice in the parietal cortex (Fig. 2c and e;
two-tailed Student’s t test, p = 0.0395). In the cortex, the
level of synaptophysin (Fig. 3a and c; two-tailed Student’s t
test, p = 0.0014) was reduced significantly while that of
GluR1 showed a trend towards a decrease in 3 × Tg-AD
mice (Fig. 3a and c; two-tailed Student’s t test, p = 0.06). In
the hippocampus, the level and the expression of GluR1
showed no significant difference between the 3 × Tg-AD
and the WT mice (Fig. 3b and c). The level of NR1in the
cortex and the expression in the parietal cortex decreased
significantly in 3 × Tg-AD mice compared to WT (Fig. 2d
and e; two-tailed Student’s t test, p = 0.0014; Fig. 3a and c;
two-tailed Student’s t test, p = 0.004). No significant difference was found in the level of PSD95 between the two
groups by Western blot in the cortex and the hippocampus (Fig. 3a and c). The analysis of the level of the ratio of
pCREB and CREB in the cortex showed a significant decrease in 3 × Tg-AD compared to WT mice (Fig. 3a and c;
two-tailed Student’s t test, p = 0.002). Human-specific
monoclonal antibody 43D to tau was used to confirm the

3 × Tg-AD mice genotype compared to WT (Fig. 3a and
b). Collectively, these findings showed dendritic and synaptic deficits and decreased CREB activity in 3 × Tg-AD
mice as compared to their WT controls at the age of 3
months.
Effect of P021 on synaptic markers after 9 months of
treatment in 3 × Tg-AD mice

We investigated the effect of 9 months of treatment with
P021 on dendritic and synaptic plasticity both immunohistochemically and biochemically. We found a significant increase in the expression of PSD-95 in 3 × Tg-ADP021 compared to WT and 3 × Tg-AD-vh mice in the
CA1 (Fig. 4a and d; one-way ANOVA, post-hoc t test,
p = 0.0038) and CA3 regions (Fig. 4a and d; one-way
ANOVA, post-hoc t test, p = 0.0010). A significant
difference was found between 3 × Tg-AD-vh and 3 ×
Tg-AD-P021 mice in the DG (Fig. 4a and d; one-way
ANOVA, post-hoc t test, p = 0.0314) and the parietal
cortex (Fig. 4a and d; one-way ANOVA, post-hoc t
test, p = 0.0169). Western blot analysis of the hippocampus showed a trend towards a decrease in the
level of PDS-95 expression in the 3 × Tg-AD-vh mice
compared to WT mice (Additional file 1: Figure S1b
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Fig. 4 Effect of P021 on reversal of dendritic and synaptic deficits in 3 × Tg-AD mice at 9 months posttreatment. After 9 months of treatment, 3 × Tg-AD
mice fed a P021 diet (Tg-AD-P021) and vehicle-treated (Tg-AD vh) and wild-type (WT) controls mice were euthanized and the expressions of PSD-95, NR1,
and MAP2 were studied by immunohistochemical staining. Immunohistochemical staining of: a PSD-95 in CA1 (stratum radiatum and stratum pyramidae), CA3 (stratum oriens, stratum radiatum, and stratum pyramidae), dentate gyrus (DG; entire area), and the parietal cortex (all six layers); b NR1 in CA3;
and c MAP2 in DG, CA3, and parietal cortex. d Quantification of immunohistochemical staining. 3 × Tg-AD-vh showed a decrease in the expression of
PSD-95 and NR1, and P021 rescued this deficit in 3 × Tg-AD mice. *p < 0.05, **p < 0.01, by one-way ANOVA post-hoc test. Scale bar = 100 μm. WT, n = 5;
3 × Tg-AD-vh, n = 5; 3 × Tg-AD-P021, n = 5. Each maximum projection picture to be analyzed was converted to greyscale and each area to be analyzed
was selected, the threshold was adjusted, and the mean pixel intensity of the region of interest was quantified. Quantification is shown as mean ± SD

and c; two-tailed Student’s t test, p = 0.07) and a
trend towards an increase in 3 × Tg-AD-P021 compared to 3 × Tg-AD-vh mice (Additional file 1: Figure
S1b and c; two-tailed Student’s t test, p = 0.07); more
details can be found in the supplemental material.
We found that the NR1 expression in the CA3 region
increased in 3 × Tg-AD-P021 compared to WT and
3 × Tg-AD-vh mice (Fig. 4b and d; one-way ANOVA,
post-hoc t test, p = 0.0091).
A trend toward a decrease was found in MAP2 expression in the CA3 (Fig. 4c and d; one-way ANOVA, posthoc t test, p = 0.09), the DG (Fig. 4c and d; two-tailed
Student’s t test, p = 0.0416) and the parietal cortex (Fig. 4c
and d; one-way ANOVA, post-hoc t test, p = 0.0392) in
the 3 × Tg-AD-vh compared to WT mice. However, no
apparent effect of P021 to prevent this deficit was

detected. In the cortex, the analysis of the level of synapsin
1 showed no difference among the three groups by
Western blot (Additional file 1: Figure S1a and c). The
level of synaptophysin was significantly decreased in 3 ×
Tg-AD-vh compared to WT mice (Additional file 1:
Figure S1a and c; two-tailed Student’s t test, p = 0.0339)
but there was no significant difference between 3 × TgAD-P021 and 3 × Tg-AD-vh mice (Additional file 1: Figure
S1a and c). These findings suggested a partial preventive
effect of 9 months of treatment with P021 on synaptic
deficit in 3 × Tg-AD mice.
Effect of P021 on prevention of synaptic deficit after 15
months of treatment

The immunohistochemical analysis of the expression of
MAP2 showed that there was a trend towards a decrease
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Fig. 5 Prevention of dendritic and synaptic deficits by P021 in 3 × Tg-AD mice at 15 months posttreatment. After 15 months, P021- (Tg-AD-P021)
and vehicle-treated (Tg-AD vh) animals were euthanized, and expressions of MAP2, synapsin 1, GluR1, synaptophysin, and NR1 were studied
immunohistochemically. a Immunohistochemical staining of MAP2 in CA1 (stratum radiatum and stratum pyramidae), CA3 (stratum oriens,
stratum radiatum, and stratum pyramidae), dentate gyrus (DG; entire area), and parietal cortex (all six layers); b synapsin 1 in CA1, CA3, and parietal
cortex; c GluR1 in CA1; d synaptophysin in CA1 and parietal cortex; e NR1 in DG and parietal cortex. f Quantification of immunohistochemical
staining. The 3 × Tg-AD-vh mice show a deficit in the expression of MAP2 and GluR1, and P021 was able to rescue this deficit. *p < 0.05, **p <
0.01, by one-way ANOVA post-hoc test. Scale bar = 100 μm. Wild-type (WT), n = 5; 3 × Tg-AD-vh, n = 4; 3 × Tg-AD-P021, n = 5. Each maximum
projection picture to be analyzed was converted to greyscale and each area to be analyzed was selected, the threshold was adjusted, and the
mean pixel intensity of the region of interest was quantified. Quantification is shown as mean ± SD

in CA1 in 3 × Tg-AD-vh mice (Fig. 5a and f; two-tailed
Student’s t test, p = 0.06); P021 treatment was detected
at 15 months post-treatment to significantly prevent the
synaptic deficit in the CA1 (Fig. 5a, f; one-way ANOVA,
post-hoc t test, p = 0.0065). In the CA3 region a trend
towards a decrease was detected in 3 × Tg-AD-vh as
compared with WT mice (Fig. 5a and f; two-tailed
Student’s t test, p = 0.09) and P021 was found to rescue
this deficit (Fig. 5a and f; one-way ANOVA, post-hoc t
test, p = 0.0226). A significant preventive effect of P021
was found in 3 × Tg-AD-P021 compared to 3 × Tg-ADvh mice in the DG (Fig. 5a and f; one-way ANOVA,
post-hoc t test, p = 0.0239) and the parietal cortex (Fig. 5a
and f; one-way ANOVA, post-hoc t test, p = 0.0491).
The expression of synapsin 1 showed a decrease in the
CA1 region (Fig. 5b and f; two-tailed Student’s t test, p
= 0.0395), and a trend in the CA3 region (Fig. 5b, f; twotailed Student’s t test, p = 0.07) and the parietal cortex
(Fig. 5b and f; two-tailed Student’s t test, p = 0.06) in 3 ×
Tg-AD-vh compared to WT mice.

The expression of GluR1 showed a significant increase
in the 3 × Tg-AD-P021 mice in the CA1 region compared to the 3 × Tg-AD-vh mice (Fig. 5c and f; twotailed Student’s t test, p = 0.0365).
The expression of synaptophysin in the CA1 region
showed a significant increase in the 3 × Tg-AD-P021 compared to WT mice (Fig. 5d and f; two-tailed Student’s t
test, p = 0.0450) and a trend towards an increase in the
parietal cortex in 3 × Tg-AD-P021 compared to WT mice
(Fig. 5d and f; two-tailed Student’s t test, p = 0.0623). The
analysis of the expression of NR1 showed that it increased
in the DG (Fig. 5e and f; one-way ANOVA, post-hoc t test,
p = 0.0306) and the parietal cortex (Fig. 5e and f; one-way
ANOVA, post-hoc t test, p = 0.0476) of the 3 × Tg-ADP021 compared to WT mice.
Level of synapsin1 in the cortex showed a preventive effect of P021 (Additional file 1: Figure S2a and c;
p = 0.0003) in 3 × Tg-AD-P021 mice. Similarly, we
found an increase in the level of synaptophysin in the
cortex of the 3 × Tg-AD-P021 mice compared to 3 ×
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Tg-AD-vh mice (Additional file 1: Figure S2a and c;
two-tailed Student’s t test, p = 0.0045). The NR1 expression showed a trend towards a positive effect of P021
(Additional file 1: Figure S2a and c). In the hippocampus
we found a trend towards a positive effect of P021 on
levels of MAP2 and synapsin1 (Additional file 1: Figure
S2b and c; two-tailed Student’s t test, p = 0.05 and p =
0.06, respectively). Collectively, these findings revealed
that 15 months of treatment with P021 can prevent
dendritic and synaptic deficits in 3 × Tg-AD mice.
Effect of P021 on synaptic and dendritic deficits after 18
months of treatment

We found a significant increase in synapsin 1 expression
in the CA1 region in 3 × Tg-AD-P021 compared to WT
mice (Fig. 6a and c; two-tailed Student’s t test, p =
0.0384) and a trend towards an increase compared to
3 × Tg-AD-vh mice (Fig. 6a and c; two-tailed Student’s t
test, p = 0.0791). The expression of NR1 in the parietal
cortex was decreased in the 3 × Tg-AD-vh compared to
WT mice (Fig. 6b and c; two-tailed Student’s t test, p =
0.0305) and there was a trend towards an increase in
3 × Tg-AD-P021 compared to 3 × Tg-AD-vh mice (Fig. 6b
and c; two-tailed Student’s t test, p = 0.05).
We found that P021 treatment significantly increased
the level of synaptophysin in the cortex but not the
hippocampus in the 3 × Tg-AD mice (Fig. 6d and f; oneway ANOVA, post-hoc t test, p = 0.03). The MAP2 level
was significantly increased in the cortex of 3 × Tg-ADP021 compared to 3 × Tg-AD-vh animals (Fig. 6d and f;
two-tailed Student’s t test, p = 0.045). The level of PSD95 in the hippocampus showed a trend towards an increase in 3 × Tg-AD-P021 compared to 3 × Tg-AD-vh
mice (Fig. 6e and f; two-tailed Student’s t test, p = 0.09).
GluR1 expression was significantly decreased in the
hippocampus of 3 × Tg-AD-vh mice (Fig. 6e and f; oneway ANOVA, post-hoc t test, p = 0.02) and P021 treatment
showed a trend in rescuing this (Fig. 6e and f; two-tailed
Student’s t test, p = 0.06). The level of the ratio of pCreb
and Creb showed a significant increase in the 3 × Tg-ADP021 group compared to the other two groups (Fig. 6e and
f; one-way ANOVA, post-hoc t test, p = 0.0007). The
GluR2/3 level showed a significant increase in the WT
group compared to the other two groups (Fig. 6e and f;
one-way ANOVA, post-hoc t test, p = 0.0002). Collectively,
these findings revealed that chronic treatment with P021
can prevent dendritic and synaptic deficits and loss of
CREB activity in 3 × Tg-AD mice.
Effect of P021 on neurogenesis

The effect of P021 on neurogenesis was investigated at 9
months posttreatment by immunohistochemical Ki-67
staining, a cell proliferation marker that measures early
stages of the neurogenesis, and by DCX staining, a
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marker for immature newly born neurons. As expected, we
found that the number of DCX-positive cells was
significantly reduced in the 3 × Tg-AD-vh compared to WT
mice (Fig. 7a and c; two-tailed Student’s t test, p = 0.0009)
and P021 rescued this deficit (Fig. 7a and c; one-way
ANOVA, post-hoc t test, p < 0.0001). Remarkably, the level
of neurogenesis was rescued to more than the level in the
WT group with P021 (Fig. 7a and c; one-way ANOVA,
post-hoc t test, p < 0.001). Similarly, a decrease in the
number of Ki-67-positive cells was observed in the 3 × TgAD-vh mice compared to WT mice (Fig. 7b and c; twotailed Student’s t test, p = 0.0057) and this deficit was rescued with the P021 treatment (Fig. 7b and c; p < 0.0001).
Effect of P021 on rescuing cognitive deficit
Treatment with P021 can rescue reference memory deficit

The 3 × Tg-AD mice are known to be cognitively impaired very early in the disease process at around 2–3
months of age with regards to spatial reference memory
[15, 24] and episodic memory [25]. Since the Morris
Water Maze task measures spatial reference memory
that is mainly hippocampal-dependent, which is affected
early in AD patients, we investigated the effect of P021
treatment on prevention of this impairment in 3 × TgAD mice. The Morris Water Maze task was conducted
after 9 months of treatment with P021, when the animals were aged 12 months. During the task animals
went through four training trials per day for 4 days for a
total of 16 trials. There was no difference in the swim
speed during the 4 training days (data not shown). The
regression analysis of the latency to escape to the hidden
platform showed that the 3 × Tg-AD-vh mice took longer than the WT mice (Fig. 8b; p < 0.001) and the 3 ×
Tg-AD-P021 mice (Fig. 8b; z = 4.78, p = 0.031). The analysis of distance by day showed that 3 × Tg-AD-vh mice
learned slower than WT mice (Fig. 8; p <0.0001) and
3 × Tg-AD-P021 animals (Fig. 8; p = 0.039), and that they
traveled farther to find the escape platform. These data
showed that the 3 × Tg-AD-vh mice were impaired and
that P021 was able to reverse this impairment.
To evaluate retention memory in the 3 × Tg-AD mice,
two probe trials (PT) were conducted. The percent of time
spent in the target quadrant and the number of crossings of
the previous place of the platform were determined to
evaluate the performance of the animals. During PT1, the
3 × Tg-AD-vh mice spent significantly less time in the target quadrant compared to WT mice (Fig. 8d; post-hoc
Bonferroni-adjusted test, p < 0.05) and P021 treatment was
able to reverse this impairment (Fig. 8d; post-hoc
Bonferroni-adjusted test, p < 0.01). A similar trend was seen
in the number of visits to the previous place of the platform
but there was no significant difference between the three
groups (Fig. 8f). During PT2, the analysis of the percent of
time in the target quadrant showed that the 3 × Tg-AD-vh
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Fig. 6 Prevention of dendritic and synaptic deficits and rescue of CREB activity loss by P021 in 3 × Tg-AD mice at 18 month posttreatment. After 18
months, P021- (Tg-AD-P021) and vehicle-treated (Tg-AD vh) mice were euthanized and expressions and/or levels of synapsin 1, NR1, synaptophysin, MAP2,
phosphor- (pCREB) and total CREB, synapsin 1, GluR1, and PSD 95 were studied immunohistochemically or by Western blot. a Immunohistochemical
analysis of synapsin 1 expression in CA1 (stratum radiatum and stratum pyramidae) and b NR1in parietal cortex (all six layers). c Quantification
of immunohistochemical staining shown in a and b. d Western blots of synaptic proteins in the whole cortex and e the whole hippocampus.
f Relative quantification of the blots. All blots were normalized against the loading control GAPDH. The level and the expression of several
synaptic markers were deficient in the 3 × Tg-AD-vh mice and P021 was able to rescue this deficit. *p < 0.05, ***p < 0.001, by one-way ANOVA
post-hoc test. Scale bar = 100 μm. Wild-type (WT), n = 5; Tg-AD-vh, n = 5; Tg-AD-P021, n = 5. Each maximum projection picture to be analyzed
was converted to greyscale and each area to be analyzed was selected, the threshold was adjusted, and the mean pixel intensity of the region
of interest was quantified. Quantification is shown as mean ± SD

mice spent less time compared to the WT mice
(Fig. 8e; p < 0.05). Furthermore, the analysis of the
number of crossings of the previous place of the platform showed that the 3 × Tg-AD-vh mice had made
fewer visits compared to the WT mice (Fig. 8g;
Student’s t test, p =0.0094) and that P021 reversed this
impairment (Fig.8g; Student’s t test, p = 0.007). Collectively, these results suggest that memory retention was
compromised in 3 × Tg-AD-vh mice and that the 9month treatment with P021 rescued this impairment.
Treatment with P021 can rescue neophobia and short-term
spatial memory impairment

Neophobia The neophobia test is employed to measure the rodent’s fear of discovering novelty, in this

case a novel object. Neophobia is controlled by the
amygdala and the ventral region of the hippocampus
[26]. In this test, each animal was exposed to an
unfamiliar object in the center of an open-field apparatus and left to explore it for 5 min. It was
conducted during the first habituation session of the
novel object location test. Neophobic animals visit
the center of the arena less and explore the novel
object less. The statistical analysis of the percent of
time spent in the center exploring the novel object
showed that both the WT and 3 × Tg-AD-vh mice
spent similar time exploring the new object, while
the P021-treated mice spent significantly more time
exploring the novel object compared to the other
two groups (Fig. 9a; one-way ANOVA post-hoc test,
p = 0.0086).
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age of 18 months had impairment in short-term spatial
memory and that the approximate 15 months of treatment with P021 reversed this impairment.

Fig. 7 Rescue of DG neurogenesis deficit after 9 month posttreatment
with P021 in 3 × Tg-AD mice. After 9 months of treatment, P021- (TgAD-P021) and vehicle-treated (Tg-AD vh) mice were killed and their
brains were analyzed for neurogenesis by doublecortin (DCX) and Ki67
immunohistochemical stainings. a DCX and TOPRO staining in wildtype (WT), 3 × Tg-AD-vh, and Tg-AD-P021mice; b Ki-67 and TOPRO
staining in WT, 3 × Tg-AD-vh, and 3 × Tg-AD-P021 mice. c Densiometric
quantification of the number of DCX-positive and Ki-67-positive cells.
Labeled cells in the granule cell layer and the hilus of the DG of the
hippocampus were manually quantified using a 40× oil objective of a
Nikon 90i fluorescent microscope. The number of DCX-positive cells
and Ki-67-positive cells was analyzed as the percent of control.
Neurogenesis was deficient in the 3 × Tg-AD-vh and P021 was able to
boost it in the P021-treated mice. Arrowheads indicate positive cells.
**p < 0.01, ***p < 0.001, by one-way ANOVA post-hoc test. Scale bar =
50 μm. Quantification is shown as mean ± SD

Short-term spatial memory impairment The novel object location in the open field is employed to measure a
hippocampal function since this brain structure is
known to be implicated in associating objects with locations [27]. The test was conducted 24 h after the last habituation session and it comprised a sample phase and a
test phase. The analysis of the data from the sample
phase showed that, as expected, there was no difference
in exploring the two identical locations between the
three groups of mice (Fig. 9b). However, the test phase
showed that the 3 × Tg-AD-vh mice spent more time investigating the familiar location than the novel one,
while the WT and 3 × Tg-AD-P021 groups spent more
time exploring the novel location than the familiar one
(Fig. 9c; ANOVA post-hoc test, p = 0.0072). Together,
these data showed that the 3 × Tg-AD-vh mice at the

Discussion
The AD brain undergoes a slow chronic progressive
neurodegeneration in which the hippocampus is most
affected. At early stages of the disease the brain attempts
to repair itself by promoting dentate gyrus neurogenesis
and synaptogenesis but, probably because of insufficient
appropriate neurotrophic support, this attempt does not
succeed beyond a limited time and the degree of dementia keeps advancing [1–7]. Employing 3 × Tg-AD mice as
a model of this phenomenon [15], in the present study
we found that by providing neurotrophic support with
P021 we can rescue synaptic deficit and reverse cognitive impairment. The use of transgenic mouse models
has helped understand the molecular mechanisms of AD
and has facilitated preclinical studies that could lead to
development of potential AD drugs. The 3 × Tg-AD
mouse model has proven to be a biologically relevant
model to AD pathology. As in AD, the 3 × Tg-AD mice
develop deficiency in episodic [24] and spatial reference
memories as early as 2–3 months of age that deteriorate
with the severity of the disease with advancing age [23].
Also as in AD, in 3 × Tg-AD mice Aβ and tau pathologies
and neurodegeneration develop in an age-dependent progressive manner and with similar brain distribution of the
lesions. Furthermore, in a separate study, we found that,
reminiscent to AD, the 3 × Tg-AD mice show synaptic
compensation [15].
In the present study we found that at 3 months of age,
before the start of P021 treatment, there were dendritic
and synaptic deficits as seen by the decrease in the levels
of MAP2, synaptophysin, PSD-95, and NR1 in 3 × TgAD mice. These findings are consistent with a reduction
in synaptophysin expression during early AD reported
previously [28–30]. Dendritic spine loss in 5- to 6month-old 3 × Tg-AD mice under short-term modern
life-like stress was also reported previously [31]. At 9
months posttreatment we found P021 was able to rescue
synaptic deficit as seen immunohistochemically by PSD95 and NR1 staining. At 15 months posttreatment P021
was also able to rescue both dendritic and synaptic deficits as seen by an increase in levels and expressions of
MAP2, synaptophysin, synapsin 1, GluR1, and NR1 both
immunohistochemically and biochemically. Similar data
were reported previously in studies where 6- to 11month-old animals were treated with P021 or its parent
molecule, Peptide 6 [8, 13, 20, 21, 23, 32, 33]. In the
present study, at 18 months posttreatment P021 prevented synaptic deficit as shown by immunohistochemical stainings and Western blot. Thus, collectively, the
present study shows that early chronic treatment with
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Fig. 8 Reversal of reference memory impairment at 9 months posttreatment with P021 in 3 × Tg-AD mice. A set of animals separate from those
employed for immunohistochemical and biochemical studies (Figs. 2, 3, 4, 5, 6 and 7) were treated with P021 diet (Tg-AD-P021) or vehicle diet
(Tg-AD vh) and tested for behavioral changes to study the effect of the treatment on reversal of cognitive impairment in 3 × Tg-AD mice by the
Morris Water Maze task. a Latency to escape; b distance traveled; c percent of time in target quadrant in probe trial 1 (PT1); d in PT2; e number
of platform crossings in PT1 and f and in PT2. Animals were trained for four trials/day for 4 days. PT1 was conducted at 24 h after the last training
session; PT2 was conducted at 20 days from PT1. The 3 × Tg-AD-vh mice were impaired in the Morris Water Maze task and P021 was able to
prevent this deficit. *p < 0.05, **p < 0.01, ***p < 0.001. Wild-type (WT), n = 20; 3 × Tg-AD-vh, n = 15; 3 × Tg-AD-P021, n = 14. Data are shown as
mean ± SD. AL adjacent left, AR adjacent right; Oq opposite quadrant, Tq target quadrant

P021 can be effective even until later age in rescuing
neuronal plasticity deficits in 3 × Tg-AD mice.
The level of neurogenesis was investigated by the
quantification of the number of DCX-positive and Ki67-positive cells in the DG area at 9 months posttreatment with P021. The results showed that neurogenesis
was defective in 3 × Tg-AD-vh mice and that the treatment with P021 was able to rescue this deficit. This
neurogenic effect of P021 could be through the inhibition of the leukemia inhibitory factor (LIF) signaling
pathway or the increase in the BDNF expression as
described by us previously [21]. These results are in
agreement with those shown previously when P021 was
injected subcutaneously into normal adult C57Bl6/J
mice [13] or by oral gavage to a rat model of cognitive
aging [12]. Similar data were also reported with 7,8-dihydroxyflavone (7,8-DHF) which is a neurotrophic compound that acts as a BDNF agonist [34, 35]. The rescue
of cognitive impairment by P021 treatment found in the
present study is consistent with similar beneficial effects

shown previously with 7,8-DHF [36, 37] and other
BDNF agonist compounds [38, 39].
The results of this study emphasize the importance of
early intervention in human clinical trials, especially during the period where the brain still has the capacity to
repair itself and before extensive synaptic and neuronal
loss. This way, a healthy neuronal network can be preserved and can prevent or slow down the progression of
AD. Since sporadic AD is not detected before the appearance of the first clinical symptoms, the strategy that
we are proposing can benefit from the number of reliable biomarkers such as cerebrospinal fluid (CSF) levels
of tau and Aβ and neuroimaging, especially with tau and
Aβ tracers developed recently in the field. For instance,
biomarkers can be used to define people that are at risk
for developing AD and then the prevention treatment
with P021 can be initiated. In the present preclinical
study of almost 2 years, P021 did not show any severe
side effects or safety issues. However, more extensive
pharmacokinetic and pharmacodynamic studies will be
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Fig. 9 Reversal of neophobia and short-term spatial memory impairment with P021 in 3 × Tg-AD (Tg-P021) mice. a Neophobia test results. b Sample
phase and c test phase of the novel object location task. In the neophobia test mice were exposed to an unfamiliar object in the center of the openfield apparatus for 5 min and the percent of exploration time was recorded. The novel object location test comprised a habituation phase, a sample
phase, and a test phase. During habituation, the animals were trained a total of six sessions, two sessions/day, and each session lasted 10 min within 2
h of intertrial interval. The sample phase and the test phase were conducted 24 h after the last habituation session. The test phase was 1 h after the
sample phase. The vehicle-treated mice (Tg-AD vh) were impaired in the object location task and P021 was able to prevent this deficit. *p < 0.05, **p <
0.01. Wild-type (WT), n = 20; 3 × Tg-AD-vh, n = 15; 3 × Tg-AD-P021, n = 14. Data are shown as mean ± SD

required before its safety and efficacy in AD patients can
be tested.
Although the results of the present study are encouraging they have to be interpreted with caution. While
the 3 × Tg-AD model shows synaptic and cognitive deficit very early in the disease process and mimics most of
the neuropathological features of AD and has proven to
be a suitable mouse model to help test different drugs
for AD in preclinical studies, it does not recapitulate the
mechanism and full comprehensive neuropathology of
human AD. The 3 × Tg-AD mouse is an overexpression
model which obviously does not represent the human
disease mechanism. Another limit of this study is that
we used only female mice. The decision to not use both
genders in this study was made because there are disparities between males and females in the consistency and
the aggressiveness of the pathology. Several laboratories
independently reported that only female 3 × Tg-AD animals show consistent and aggressive pathology [17–19].
The 3 × Tg-AD mouse model was generated by the coinjection of two mutated transgenes, human βAPPSwe
and tau P301L, in PS1M146v knock-in embryos. This is a
homozygous mouse line and these animals and their
genetically matched 129/Sv × C57BL/6 control WT mice
are independently bred. While a lack of littermate control is not ideal for comparing the differences between

3 × Tg-AD and the WT animals, the comparison of
P021-treated with the vehicle-treated 3 × Tg-AD mice
employed in the present study clearly showed the therapeutic beneficial effect of P021 on both neurobiology
and neurobehavior of the AD mouse model. In the
present study we employed naive animals for neurobiological studies. Our previous studies showed that P021
rescues Aβ and tau pathologies in both behaviorally
tested (Morris water maze and novel object discrimination tasks) and untested 3 × Tg-AD mice, and that the
mice kept on a vehicle diet have higher Aβ and tau pathology burden than those treated with P021; P021 decreased both pathologies markedly and rescued cognitive
deficit in 3 × Tg-AD mice [21, 40].
The sporadic form of AD which represents over 95–
99% of the cases is not caused by any mutation, which
makes this mouse model representing more the familial
form than the sporadic form of the disease. The insertion of the transgenes into the genome may knockout
other genes creating artifacts that are not present in human AD. However, this is an inherent problem for all
the transgenic mice available in the field. What explains
our choice of the 3 × Tg-AD mouse in this study is that
it shows the synaptic compensation phenomenon [15]
that is the main focus of the therapeutic intervention in
the present study.
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Conclusions
In conclusion, the prevention of dendritic and synaptic
deficits and reversal of cognitive impairment by chronic
treatment started during the period of synaptic compensation with a neurotrophic compound in an AD mouse
model shows the therapeutic potential of this strategy. Unlike neurotrophic factors which are blood–brain barrier
impermeable and cause serious side effects such as anorexia, severe cramps, and muscle pain by CNTF, treatment with P021 for around 18 months did not show any
weight loss, tumors, or signs of pain in 3 × Tg-AD mice.
Additional file
Additional file 1: Table S1. Number of animals used. Table S2.
Antibodies used. Figure S1. Rescue of synaptic deficit with P021 in 3 ×
Tg-AD mice at 9 months posttreatment. Western blots: a) cortex; b)
hippocampus; and c) relative quantification of the blots. All blots were
normalized against the loading control GAPDH. One-way ANOVA posthoc test. *p < 0.05. WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-P021, n = 5. Quantification data are shown as mean ± SD. Figure S2. Preventive effect of
P021 on levels of dendritic and synaptic markers in 3 × Tg-AD mice at 15
months posttreatment. Western blots: a) cortex; b) hippocampus; and c)
relative quantification of the blots. The 3 × Tg-AD-vh show a decrease in
the level of synaptic markers and P021 was able to rescue this deficit. All
blots were normalized against the loading control GAPDH. One-way
ANOVA post-hoc test. **p < 0.01. WT, n = 5; Tg-AD-vh, n = 3; Tg-AD-P021,
n = 5. Quantification data are shown as mean ± SD. (DOCX 5530 kb)
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